Decision Resources, Inc., announces the publication of Benign Prostatic Hyperplasia, a new study that examines how the high prevalence, morbidity, and unmet medical needs associated with benign prostatic hyperplasia (BPH) combine to provide substantial opportunity for companies able to produce effective and safe new drugs to treat this indication.


Recent advances in pharmacotherapy have focused primarily on the development of uroselective alpha blockers (i.e., agents that are more specific inhibitors of prostatic smooth muscle contraction than current alpha blockers). These agents should have fewer side effects than the current alpha blockers and thus have the potential to increase patient compliance. Notable factors in the alpha blocker field are as follows:

  -- Alpha blockers accounted for 66% of 1999 major-market sales. Leading      the pack is tamsulosin (Boehringer Ingelheim/Yamanouchi's Flomax),      which most physicians highly regard for its convenient once-daily      therapy and relative lack of hypotensive side effects. Although we      expect tamsulosin to dominate future sales of alpha blockers in the      seven major pharmaceutical markets (United States, France, Germany,      Italy, Spain, United Kingdom, and Japan), claiming 30% of the BPH      market in 2009, we forecast that emerging alpha blockers will account      for 21% of the market in that year, largely at the expense of terazosin      (Abbott's Hytrin/Flotrin/Deflox, generics) and doxazosin (Pfizer's      Cardura/Cardula/Carduran, generics).   -- Sepracor's S-doxazosin -- the S-isomer of Pfizer's doxazosin -- is      currently in U.S. Phase I clinical trials. S-doxazosin offers the      potential advantage over doxazosin of increased uroselectivity,      retaining its efficacy with a reduced side-effect profile. Of the      therapies in development for BPH, this agent appears to have the      greatest commercial promise.   -- Other uroselective alpha blockers evaluated in this study are Kissei      Pharmaceutical/Daiichi's KMD-3213, Synaptic Pharmaceuticals' SNAP-6383,      and Abbott's fiduxosin (ABT-980). Of these, KMD-3213 is the only agent      reported to be more effective than tamsulosin in preclinical studies.   -- According to experts, reformulation of existing alpha blockers is      likely to provide an additional challenge to current therapies, as the      recent European market entry of Sanofi-Synthelabo's extended-release      formulation of alfuzosin (Xatral XL) illustrates.  

Benign Prostatic Hyperplasia offers invaluable market intelligence for pharmaceutical companies developing drugs to treat this indication. This study is a Mosaic product, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit Decision Resources at

Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or


AP Archive:

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, 781-296-2553,

Selective COX-2 Inhibitors Will Maintain the Lead in the Chronic Pain Market, According to a Decision Resources Study

View Now